| |
Wednesday, March 26, 2025 | 12pm ET / 9am PT Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today. 
|
|
Today’s Big NewsMar 19, 2025 |
|
Thursday, March 27, 2025 | 11am ET / 8am PT This webinar will explore the growing need for process intensification in bioprocessing as a crucial step toward enhancing efficiency and sustainability. Join us to gain valuable insights into overcoming challenges related to bioprocess scale-up, including the adaptation of novel bioreactors, media formulations, and cell culture practices. Register now. 
|
|
| By Gabrielle Masson After serving as the director of the National Human Genome Research Institute for more than 15 years, Eric Green, M.D., Ph.D., has suddenly departed. |
|
|
|
By Kevin Dunleavy Two months after U.S. President Donald Trump proclaimed DEI programs “illegal and immoral,” Roche has reportedly scrapped its high-profile five-year plan to increase the diversity of its leadership. Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, according to Reuters. |
By Andrea Park As the college basketball March Madness tournament tips off this week, so too does Fierce Pharma Marketing’s annual #FierceMadness competition. |
By Gabrielle Masson Cell therapy biotech bit.bio is slimming its workforce down by 25% as the company pivots to focus on biomedical tools instead of drug development. |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.  
|
|
By Nick Paul Taylor A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary endpoint. But, having made a second-generation molecule its lead candidate last year, the biotech isn’t currently planning to file for batoclimab approval in myasthenia gravis or chronic inflammatory demyelinating polyneuropathy. |
By Conor Hale The brain-computer interface developer Synchron has laid out plans to build an AI model trained on the language of cognition. |
By Angus Liu A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the treatment of older patients with spinal muscular atrophy. |
By James Waldron Roche has secured its third antibody-drug conjugate deal of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. |
By Conor Hale Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to treating people with Type 2 diabetes, placing them ahead of new medications. |
By Fraiser Kansteiner After charting similar moves throughout 2024, Pfizer this week completed a sale of its remaining shares in Haleon, taking home around 2.5 billion pounds sterling ($3.2 billion) for its stake in the standalone consumer health giant. GSK, which owned a 13% stake in Haleon after the unit's 2022 demerger, sold the remainder of its position in the company last May. |
By Darren Incorvaia Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more of its load. The CAR-T firm is dropping its B-cell disease prospect CRG-023 and suspending development of its allogeneic platform, along with cutting about 90% of its workforce. |
By Andrea Park Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot. |
By Fraiser Kansteiner With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. Still, geopolitical uncertainties under the second Trump administration loom large over the Chinese contract research and manufacturing giant’s future. |
By Darren Incorvaia As fungi resistant to traditional treatments continue to spread around the globe, researchers from China Pharmaceutical University in Nanjing have identified a bacterial compound that can kill infectious fungi even if they’re resistant to other antifungals. |
By Zoey Becker After a federal guilty plea in 2020, the former OxyContin drugmaker is required to reemerge from Chapter 11 bankruptcy as a public benefit company. |
By Nick Paul Taylor The campaign asks why people readily pick up their dogs’ poop while putting off handling their own stools to get tested for colorectal cancer. |
By Emma Beavins Top officials first aimed to slash everything within 48 hours. It has since backtracked and says the HIV Prevention program may be reorganized into HRSA, or less drastically cut. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed by many major pharma companies in 2024’s fourth quarter. |
|
|---|
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
